FDA Okays Perioperative Durvalumab for Bladder Cancer
Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-okays-perioperative-durvalumab-regimen-muscle-invasive-2025a10007rs?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-okays-perioperative-durvalumab-regimen-muscle-invasive-2025a10007rs?src=rss
Comments
Post a Comment